Last updated 4 days ago

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

910 patients around the world
Available in Argentina, United States
Kodiak Sciences Inc
910Patients around the world

This study is for people with

Diabetic retinopathy
Diabetic macular edema

Requirements for the patient

From 18 Years
All Gender

Medical requirements

DME, treatment-naïve or previously-treated.
Male or female ≥18 years of age with Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%.
Capable of giving informed signed consent.
Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.
Current or history of retinal detachment (tractional or rhegmatogenous) in the Study Eye.
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloadsCareers
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy